Morgan Stanley Has Lowered Expectations for Chemours (NYSE:CC) Stock Price

Chemours (NYSE:CC - Get Free Report) had its price objective reduced by investment analysts at Morgan Stanley from $25.00 to $22.00 in a report released on Monday,Benzinga reports. The brokerage presently has an "equal weight" rating on the specialty chemicals company's stock. Morgan Stanley's target price would suggest a potential upside of 19.50% from the company's previous close.

CC has been the subject of a number of other research reports. Barclays raised their target price on Chemours from $21.00 to $23.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 5th. Royal Bank of Canada reiterated an "outperform" rating and issued a $25.00 price target on shares of Chemours in a research note on Thursday, December 12th. The Goldman Sachs Group lowered their price objective on Chemours from $24.00 to $21.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. BMO Capital Markets raised their price target on shares of Chemours from $30.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, October 7th. Finally, Mizuho cut their price objective on Chemours from $22.00 to $21.00 and set a "neutral" rating for the company in a report on Tuesday, January 7th. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $23.75.

Chemours Trading Up 4.4 %

NYSE:CC traded up $0.77 during trading hours on Monday, reaching $18.41. The company's stock had a trading volume of 1,768,890 shares, compared to its average volume of 1,839,836. The firm has a 50-day simple moving average of $19.27 and a 200-day simple moving average of $19.86. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. Chemours has a 1 year low of $15.10 and a 1 year high of $32.48. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of 36.82 and a beta of 1.83.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.32 by $0.08. The firm had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The company's revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.64 earnings per share. Research analysts expect that Chemours will post 1.35 EPS for the current fiscal year.

Insider Buying and Selling

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the completion of the transaction, the senior vice president now owns 16,645 shares in the company, valued at $343,552.80. This trade represents a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.47% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. KBC Group NV grew its holdings in Chemours by 19.5% during the 3rd quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company's stock valued at $91,000 after purchasing an additional 728 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Chemours by 166.9% during the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock valued at $26,000 after buying an additional 731 shares during the period. GAMMA Investing LLC grew its position in Chemours by 99.7% in the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock valued at $26,000 after acquiring an additional 765 shares during the last quarter. State of Alaska Department of Revenue lifted its position in shares of Chemours by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 17,205 shares of the specialty chemicals company's stock worth $349,000 after purchasing an additional 1,175 shares during the last quarter. Finally, Signaturefd LLC boosted its stake in shares of Chemours by 163.7% during the third quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company's stock valued at $40,000 after purchasing an additional 1,216 shares during the period. Institutional investors own 76.26% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.